SABCS 2025

A milestone for ET in HR+ HER2- and important follow-up…

Where is the future of SERDs in MBC?

Patients contribution is essential

Therapy optimization: Endocrine approaches in…

SERDs in early breast cancer - the new era has begun?

Revolution in adjuvant endocrine therapy?

Surgery remains soc in low risk EBC

Giredestrant will replace current adjuvant therapy

AI based prognostic test

PALLAS trial and ctDNA

SERDs now in adjuvant therapy

Quality of live data DB11

Significant innovations in early and metastatic HER2+…

ctDNA analysis could optimize the approach in HER2+

sTILs with deep learning AI

Optimized endocrine therapy for premenopausal patients

Olaparib neoadjuvant with high PCR rates

Platinum adjuvant in TNBC

Carboplatin in adjuvant setting of TNBC

Otimização da terapia: abordagens endócrinas em…

SERDy we wczesnym raku piersi -początek nowej epoki?

La chirurgia rimane lo standard di cura nei casi di…

El análisis del ADN libre circulante podría optimizar…

Risultati dello studio ALTTO in base alla terapia…

Phase 2 combination of elacestrant with everolimus or…

The significance of SG is more clearly defined

Updated results of VIKTORIA-1

Triple-positive MBC: less chemotherapy, more endocrine…

Traditional chemotherapy should not be forgotten as…

Make a hot tumor out of a cold tumor

Palbociclib likely delays CNS progression

ASCENT-07 a negative trial

Chemotherapy-free treatment: a promising therapeutic…

No improvement over standard therapy

Elacestrant is a good combination partner for HR+ HER2+…

Elacestrant as oral endocrine backbone

Monitoring of ILD

New evidence for oral SERDs

ctDNA Dynamics as a biomarker of response

Significant innovations in early and metastatic HER2+…

Maintenance therapy HER2+ Tucatinib as a new option

Tucatinib a new SERD in the adjuvant setting

Sem melhorias em relação à terapia padrão

Tucatinib, un nouveau SERD dans le cadre d'un…

La dinamica del ctDNA come biomarcatore di risposta

Jeszcze nie czas na rezygnację z tradycyjnej…

Elacestrant come partner endocrino orale

Résultats actualisés de VIKTORIA-1

Risultati aggiornati di VIKTORIA-1